We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Cisco Systems, CVS Health, Moderna, Pfizer and Hilton Worldwide
Read MoreHide Full Article
For Immediate Release
Chicago, IL – December 7, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Cisco Systems, Inc. (CSCO - Free Report) , CVS Health Corporation (CVS - Free Report) , Moderna, Inc. (MRNA - Free Report) , Pfizer Inc. (PFE - Free Report) and Hilton Worldwide Holdings Inc. (HLT - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Cisco, CVS Health and Moderna
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, CVS Health Corporation and Moderna. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Cisco have declined -8.0% in the year-to-date period against the Zacks Computer - Networking industry’s loss of -7.9%. The Zacks analyst believes that weakness in the commercial, service provider and enterprise end markets and coronavirus crisis-led supply chain constraints is likely to weigh on the company’s revenues. Also, weak demand for servers, and sluggish enterprise IT spending, remain concerns.
However, Cisco's fiscal first-quarter results actually benefited from robust adoption of identity and access, advanced threat and unified threat management security solutions amid high growth in Internet traffic. Ongoing momentum in Webex video conferencing and business productivity offerings on account of COVID-19 induced work-from-home demand environment remains noteworthy. Also, strong demand for Catalyst 9000 family of switches aided growth. Moreover, the company provided encouraging guidance for the fiscal second-quarter.
CVS Health shares have outperformed the Zacks Retail - Pharmacies and Drug Stores industry over the past three-month period (+20.4% vs. +18.1%). In fact, the company ended the third quarter with earnings and revenues surpassing the respective Zacks Consensus Estimate. The Zacks analyst believes that the COVID-19 pandemic affected the Pharmacy Services business as new therapy prescriptions reduced due to lower provider visits. However, this segment delivered double-digit operating income growth reflecting strength in specialty pharmacy along with favorable purchasing economics.
Meanwhile, the year-over-year Retail/LTC revenue rise was primarily driven by increased prescription volume and higher front store revenues. Health Care Benefits arm benefitted from strong Medicare AEP. Increased guidance amid the pandemic scenario is another positive.
Moderna shares have gained +704.0% in the year-to-date period against the Zacks Medical - Biomedical and Genetics industry’s rise of +4.6%. The company’s coronavirus vaccine candidate achieved 94.1% efficacy rate in primary analysis and a EUA is anticipated by year-end. It is also developing several promising mRNA-based pipeline candidates, targeting a wide range of indications. The Zacks analyst believes that these candidates also attract partnerships with big pharma companies, thus generating funds through upfront and milestone payments, and reducing research and marketing costs.
However, Moderna's sole dependence on partners for revenues is a concern. Early to mid-stage nature of its pipeline runs a high degree of risk. Any development setbacks would be a major disappointment for the company.
Other noteworthy reports we are featuring today include Pfizer and Hilton Worldwide Holdings Inc.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Cisco Systems, CVS Health, Moderna, Pfizer and Hilton Worldwide
For Immediate Release
Chicago, IL – December 7, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Cisco Systems, Inc. (CSCO - Free Report) , CVS Health Corporation (CVS - Free Report) , Moderna, Inc. (MRNA - Free Report) , Pfizer Inc. (PFE - Free Report) and Hilton Worldwide Holdings Inc. (HLT - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Cisco, CVS Health and Moderna
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, CVS Health Corporation and Moderna. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Cisco have declined -8.0% in the year-to-date period against the Zacks Computer - Networking industry’s loss of -7.9%. The Zacks analyst believes that weakness in the commercial, service provider and enterprise end markets and coronavirus crisis-led supply chain constraints is likely to weigh on the company’s revenues. Also, weak demand for servers, and sluggish enterprise IT spending, remain concerns.
However, Cisco's fiscal first-quarter results actually benefited from robust adoption of identity and access, advanced threat and unified threat management security solutions amid high growth in Internet traffic. Ongoing momentum in Webex video conferencing and business productivity offerings on account of COVID-19 induced work-from-home demand environment remains noteworthy. Also, strong demand for Catalyst 9000 family of switches aided growth. Moreover, the company provided encouraging guidance for the fiscal second-quarter.
(You can read the full research report on Cisco here >>>)
CVS Health shares have outperformed the Zacks Retail - Pharmacies and Drug Stores industry over the past three-month period (+20.4% vs. +18.1%). In fact, the company ended the third quarter with earnings and revenues surpassing the respective Zacks Consensus Estimate. The Zacks analyst believes that the COVID-19 pandemic affected the Pharmacy Services business as new therapy prescriptions reduced due to lower provider visits. However, this segment delivered double-digit operating income growth reflecting strength in specialty pharmacy along with favorable purchasing economics.
Meanwhile, the year-over-year Retail/LTC revenue rise was primarily driven by increased prescription volume and higher front store revenues. Health Care Benefits arm benefitted from strong Medicare AEP. Increased guidance amid the pandemic scenario is another positive.
(You can read the full research report on CVS Health here >>>)
Moderna shares have gained +704.0% in the year-to-date period against the Zacks Medical - Biomedical and Genetics industry’s rise of +4.6%. The company’s coronavirus vaccine candidate achieved 94.1% efficacy rate in primary analysis and a EUA is anticipated by year-end. It is also developing several promising mRNA-based pipeline candidates, targeting a wide range of indications. The Zacks analyst believes that these candidates also attract partnerships with big pharma companies, thus generating funds through upfront and milestone payments, and reducing research and marketing costs.
However, Moderna's sole dependence on partners for revenues is a concern. Early to mid-stage nature of its pipeline runs a high degree of risk. Any development setbacks would be a major disappointment for the company.
(You can read the full research report on Moderna here >>>)
Other noteworthy reports we are featuring today include Pfizer and Hilton Worldwide Holdings Inc.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.